Biology, pathology, and therapeutic targeting of RAS.

Abstract excerpt

RAS was identified as a human oncogene in the early 1980s and subsequently found to be mutated in nearly 30% of all human cancers. More importantly, RAS plays a central role in driving tumor development and maintenance. Despite decades of effort, there remain no FDA approved drugs that directly inhibit RAS. The prevalence of RAS mutations in cancer and the lack of effective anti-RAS therapies stem from RAS' core...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to ras Proteins
• Share to Signal Transduction
• Share to Antineoplastic Agents